Navigation Links
Cytopia Commences Second Phase II Study in Brain Cancer
Date:9/4/2008

tudy indicates that the compound is well absorbed after administration in capsule form. This key finding differentiates CYT997 from other vascular disrupting agents currently in development which can only be administered intravenously, limiting their clinical utility.

Enrolment into the company's Phase II study of CYT997 in relapsed multiple myeloma, a disorder of the bone marrow, is also ongoing.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase I and Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
5. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
6. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
7. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
8. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation ... of heart valves and hemodynamic monitoring, today announced that ... of Directors. "Bob is an ardent champion for ... true privilege to have him on Edwards, board as we ... , Edwards, chairman and CEO.  "Bob has provided a valuable ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... 8, 2012 Circassia Ltd, a specialty ... ragweed allergy therapy has achieved positive results in a ... with more severe symptoms achieved a significantly greater improvement ... on placebo (p≤0.05).  The results were presented at the ...
... 2012  InfuSystem Holdings, Inc. (NYSE Amex: INFU ... and related services, today announced that it has postponed ... 2011 results originally scheduled for March 8, 2012 in ... complete their audit.  The Company expects to announce financial ...
Cached Medicine Technology:Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 2Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 3InfuSystem Postpones Announcement of Fourth Quarter and Fiscal Year 2011 Earnings 2
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... 2015”, one of the industry’s premier thought leadership symposiums, hosted by Massachusetts-based ... 6. The event attracts over 250 “C”-level executives, administrators, directors of nursing, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System ... that evaluate the potential of related, experimental treatments. The collaboration moves into the next ... award Columbia Care one of five state licenses to produce and dispense medical marijuana. ...
(Date:7/31/2015)... ... 31, 2015 , ... Like nearly every other form of surgery, it shouldn't ... more effective and less intrusive and painful. Leading these advances in the United ... Loria currently stands as the only doctor in the United States who is qualified ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a ... a heart rate of 150 beats versus 100 beats, this is a big deal," ... to give life back to patients with heart disease," he adds. People with angina ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... Protection Week March 1-7, 2009 FRAMINGHAM, Mass., March 2 ... the largest increase occurring at corporations and small businesses. ... that 86 percent of data breaches could be prevented, ... Protection Program ( www.identityforce.com/MPP ) in honor of National ...
... Calif., March 2 Based on its recent,analysis ... presents Veran,Medical Technologies, Inc. with the 2009 North ... the Year in recognition of its pioneering,development of ... known as,the IG4, which enables accurate and efficient ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... to new heightsHALIFAX, March 02 /PRNewswire/ - Ocean ... Omega-3 EPA/DHA food and dietary supplement ingredients from ... develop consumer awareness of the health benefits of ... awareness campaign with an interview segment ( http://www.onc.ca/Press/Docs/SEARS-WILLIAM-12.12.08.mp3 ...
... children ages 8-11 years shows contact lens wearers ... and Social Acceptance , JACKSONVILLE, Fla., March ... children beyond simply correcting their nearsightedness -- significantly ... acceptance among friends, and ability to play sports. ...
... software and services company, today announces that it has passed,the ... (TSU) 2009 label. , Misys was ... TSU service came into existence in April 2007 for its ... , The TSU, which has more ...
Cached Medicine News:Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 2Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 2Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 4Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 3Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 4Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: